Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex by Yu-Ling Lin et al.
Lin et al. J Nanobiotechnol  (2016) 14:11 
DOI 10.1186/s12951-016-0163-3
RESEARCH
Inhibition of breast cancer 
with transdermal tamoxifen-encapsulated 
lipoplex
Yu‑Ling Lin1,2†, Chia‑Hung Chen3†, Hsin‑Yi Wu3, Nu‑Man Tsai4,5, Ting‑Yan Jian3, Yuan‑Ching Chang6, 
Chi‑Hsin Lin7, Chih‑Hsiung Wu8, Fei‑Ting Hsu9,10, Ting Kai Leung11,12,13,14*† and Kuang‑Wen Liao1,3,15*†
Abstract 
Background: Tamoxifen is currently used for the treatment of both early and advanced estrogen receptor (ER) posi‑
tive breast cancer in pre‑ and post‑menopausal women. However, using tamoxifen routinely to inhibit endogenous or 
exogenous estrogen effects is occasionally difficult because of its potential side effects.
Objectives: The aim of this study is to design a local drug delivery system to encapsulate tamoxifen for observing 
their efficacy of skin penetration, drug accumulation and cancer therapy.
Methods: A cationic liposome‑PEG‑PEI complex (LPPC) was used as a carrier for the encapsulation of tamoxifen and 
forming ‘LPPC/TAM’ for transdermal release. The cytotoxicity of LPPC/TAM was analyzed by MTT. The skin penetration, 
tumor growth inhibition and organ damages were measured in xenograft mice following transdermal treatment.
Results: LPPC/TAM had an average size less than 270 nm and a zeta‑potential of approximately 40 mV. LPPC/TAM 
displayed dramatically increased the cytotoxic activity in all breast cancer cells, especially in ER‑positive breast cancer 
cells. In vivo, LPPC drug delivery helped the fluorescent dye penetrating across the skim and accumulating rapidly in 
tumor area. Administration of LPPC/TAM by transdermal route inhibited about 86 % of tumor growth in mice bearing 
BT474 tumors. This local treatment of LPPC/TAM did not injury skin and any organs.
Conclusion: LPPC‑delivery system provided a better skin penetration and drug accumulation and therapeutic effi‑
cacy. Therefore, LPPC/TAM drug delivery maybe a useful transdermal tool of drugs utilization for breast cancer therapy.
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Background
Breast cancer incidence and mortality in Taiwan was 
increased by approximately two to three times within 
nearly two decades, and Taiwanese breast cancer patients 
tend to be younger which is different from Western 
countries such as Europe and United States [1]. The age 
specific incidence of breast cancer in Taiwan rapidly 
increases in patients aged approximately 45 years. How-
ever, the equivalent peak in diagnosis occurs 5–10 years 
later among patients in the Western countries [2, 3]. In 
addition, the proliferative effects of female hormones 
(especially estrogen) on breast glandular cells have been 
proved to play the major role in the causing mechanism 
of breast cancer [4, 5]. In our previous study, the evi-
dences from MRI images also revealed that overuse of 
estrogen or phyto-estrogen supplements can increase 
breast glandular tissue proliferation. Such proliferation 
may increase the patient’s risk of future breast cancer 
[3]. In Taiwan, higher incidence of breast cancer and 
more predominant on premenopausal age may reflect 
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closer relationship between breast cancer and estrogenic 
effects, which is different to the Western countries [2].
Tamoxifen is an antagonist of the estrogen receptor via 
its active metabolite, hydroxytamoxifen, and is clinically 
administrated as the chemotherapy for estrogen recep-
tor-positive breast cancer in pre-menopausal women [1]. 
Currently, Tamoxifen is also used typically for the treat-
ment of both early and advanced estrogen receptor posi-
tive (ER+) breast cancer in pre- and post-menopausal 
women. For growth inhibition, Tamoxifen inhibit protein 
kinase C activity and ERK1/2 signaling pathway to mod-
ulate the growth of breast cancer cells [6]. Interestingly, 
although the ER-negative cell lines were much less sensi-
tive to tamoxifen treatments than the ER-positive cells, 
Tamoxifen still caused the growth inhibition and cytotox-
icity of ER-negative cell lines (such as MDA-MB-231) [7, 
8]. The growth inhibition of Tamoxifen on ER-negative cell 
lines, are associated with a slight decrease in percentage 
of S-phase during cell mitosis [9]. The effects of tamox-
ifen-induced apoptosis in ER-negative breast cancer cells 
may be through inhibition of CIP2A/PP2A/p-Akt signal-
ing pathway [10]. Thus, tamoxifen is considered as a good 
chemotherapeutic drug for the patients with breast cancer.
Since tamoxifen’s introduction for clinical use in the early 
1970s, synthetic anti-estrogen tamoxifen citrate has been 
shown to contribute to controlling human breast cancer 
and recurrence [11]. However, the gynecologic side effects 
for routinely using tamoxifen are diverse and reflect the 
complexity of its mechanism of action. The most concern-
ing gynecologic side effect is endometrial disease in post-
menopausal women [12]. To reduce its side effect of oral 
administration, such as thrombosis and hepatic first-pass 
metabolism, as well as endometrial hyperplasia, transder-
mal delivery of tamoxifen using liposomal vehicle [13]. In 
addition, menthone in 50 % ethanol is also demonstrated 
it can enhance in vitro percutaneous absorption of tamox-
ifen [14]. Besides, Dr. Khan and his collogues showed the 
transdermal delivery of tamoxifen to the breast may avert 
the toxicity of oral tamoxifen while maintaining efficacy in 
Phase II presurgical trial [15]. However, decrease in 3.4 % 
of Ki67 after therapy in the previous study in which the 
delivery efficiency is considered it can be improved.
The cationic liposome-PEG-PEI complex (LPPC) had 
been developed for encapsulating drug and protected 
drugs’ structural stability [16–18]. LPPC helps the drugs 
rapidly penetrate into cell plasma to result in an excellent 
therapeutic effect in  vitro and in  vivo [17, 18]. Because 
LPPC can strongly capture antigens or immunomodu-
lators onto its surface, LPPC has also been used as an 
adjuvant and triggered the Th2 immune responses and 
antibodies class switch [19]. These results therefore sug-
gest that LPPC may serve as an effective drug carrier and 
a useful anticancer tool.
In this study, LPPC was designed as a local drug deliv-
ery system for tamoxifen encapsulation and to observe 
their efficacy of skin penetration and therapeutic effi-
ciency. LPPC/TAM has higher cytotoxicity in all breast 
cancer cell lines. In vivo studies showed that LPPC/TAM 
can efficiently penetrate across the skins of the mice and 
increase the drug accumulation in tumor. LPPC/TAM also 
significantly inhibit the tumor growth of the BT474 tumor. 
Therefore, the LPPC/TAM is worthy to further develop as 
an anti-breast cancer drug by transdermal treatment.
Results
The characteristics of LPPC/TAM
The particle sizes of different LPPC/TAM mixtures 
(weight ratios of LPPC/TAM from 1:0.25 to 1:2) ranged 
from 180 to 230 nm (Fig. 1a). The average zeta-potential 
of these different LPPC/TAM mixtures ranged from 38 
to 60 mV (Fig. 1b). For TAM encapsulation, the maximal 
encapsulation capacity of 1 mg of LPPC was ~6200 µg of 
TAM at 1:2 (w/w) ratios of LPPC/TAM (Fig. 1c). Accord-
ing to the results of particle size, zeta-potential, and 
BP encapsulation capacity assessments, the 1:2 ratio of 
LPPC/TAM was chosen for the following experiments.
To understand drug release from LPPC/TAM com-
plexes, in vitro drug release was determined. The kinetics 
of drug release showed that only 35–42 % of the encap-
sulated TAM was released from LPPC/TAM after incu-
bation at 4  °C (Fig.  1d). Approximately 90 and 98  % of 
the encapsulated TAM had been released into the media 
after 48 h-incubation at 25 and 37 °C. When LPPC/TAM 
was incubated in PBS solution with different pH value at 
37 °C, the kinetics of TAM release was similar (Fig. 1e).
Moreover, the stability of LPPC/TAM was investigated 
for further analysis and application. Figure  2a, b indi-
cated that the particle sizes and zeta-potentials did not 
significantly change at 8 weeks as well as fresh prepara-
tion (0 week). Over 90 % of TAM retained in LPPC/TAM 
complexes within 6  weeks, even 70  % of TAM retained 
at 8  week (Fig.  2c). Since drug storage is an important 
issue for the future clinical application, LPPC/TAM were 
processed by freeze drying for storage. After 8  weeks 
incubation, freeze dried LPPC/TAM were rehydrated 
with DDW, and then the particle sizes, zeta-potentials 
and TAM contents in LPPC were measured. Figure  2d, 
e showed that the characteristics of freeze dried LPPC/
TAM were similar to fresh prepared LPPC/TAM and 
TAM was stably kept in LPPC within 8 weeks.
The cytotoxic activity of LPPC/TAM against breast cancer 
cells
To determine whether LPPC/TAM could enhance the 
cytotoxicity of TAM in different types of breast cancer 
cells, such as ER-positive MCF-7 and BT474 cells and 
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ER-negative MDA-MB-231 cells were analyzed by MTT 
assay. The results of Fig.  3a, b indicated that the LPPC 
complexes enhanced the cytotoxic effects of TAM on 
ER+ cells, such as MCF-7 and BT474 cells. Interest-
ingly, LPPC also increased the cytotoxic effects of TAM 
on MDA-MB-231 (ER−) cells (Fig. 3c). The cytotoxicity 
Fig. 1 The characteristics of LPPC/TAM. TAM encapsulated in 10 mg of LPPC at various weight ratios. The (a) particle size, (b) zeta‑potential and (c) 
TAM encapsulation of LPPC/TAM were measured. *p < 0.05 or ** p < 0.01, compared with the LPPC group. d TAM release from LPPC/TAM in PBS at 
4, 25 and 37 °C. *p < 0.05, 37 °C group was compared with the 4 °C group; #p < 0.05, 25 °C group was compared with the 4 °C group. e TAM release 
from LPPC/TAM in PBS with pH 6.0, 7.4 or 8.0 at 37 °C. After the incubation, the percentage of TAM in each supernatant was measured and com‑
pared with the total amount of TAM (n = 6)
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of LPPC/TAM was similar to TAM in HEK293 cells 
(Fig. 3d).
Transdermal LPPC/DiI absorption in vivo
This study examined the effect of LPPC encapsulation of 
drug on the permeability in transdermal drug delivery 
using the DiI as a florescent probe. The results showed 
that the permeability of cream/DiI were detectable after 
12  h. However, LPPC/DiI significantly facilitated the 
passage of drug through skin after treatment for 30 min 
(Fig. 4a). In tumor area, LPPC enhanced a large number 
of DiI accumulated after 2  h treatment, while the <5  % 
DiI accumulation in the cream/DiI group (Fig. 4b).
Effects of LPPC/TAM on tumor growth inhibition 
and organs damage
Athymic mice bearing BT474 tumors were treated with 
cream/TAM (25  mg/kg), empty LPPC or LPPC/TAM 
Fig. 2 Stability of LPPC/TAM. LPPCs and LPPC/TAMs were storage at 4 °C for 8 weeks. a Particle size, b zeta‑potential and c TAM amount in LPPC 
were measured at different storage time (n = 6). LPPC/TAMs were processed by freeze drying and storage at 4 °C for 8 weeks. d Particle size, e zeta‑
potential and f TAM amount in LPPC were measured (n = 3). *p < 0.05, compared with the 0 week
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(containing 25  mg/kg TAM) every day by application. 
The animals treated with LPPC/TAM showed a signifi-
cant suppression of BT474 tumor growth compared with 
the control group by approximately 82 %, even two mice 
with tumor had been cured (Fig.  5a). These results also 
showed that LPPC/TAM was more effective than cream/
TAM on inhibiting BT474 tumor growth. Additionally, to 
evaluate the tissue damage induced by LPPC/TAM treat-
ment, pathology of organs had been analyzed. Figure 5b 
showed that LPPC/TAM did not hurt any organs and 
induce any irritation of the skin in the treated mice 
(Fig. 5c). Therefore, this local treatment with LPPC/TAM 
maybe a safe and efficient breast cancer therapeutics.
Discussion
Transdermal drug delivery system offers sustainable 
release of drugs in local area. However, permeation of the 
most of the drugs across the skin barrier remains a major 
limitation. In this study, LPPC/TAM successfully passed 
through in vivo animal skin, helped drugs accumulation in 
subcutaneous tumor (Fig.  4) and efficiently inhibited the 
tumor growth (Fig. 5). LPPC/TAM significantly increased 
the inhibition of subcutaneous tumor growth by transder-
mal treatment due to positive charge on its surface. These 
cationic liposomes, which are promising carriers for trans-
dermal treatment, have been found to efficiently pass the 
skin cells into tumors [20, 21]. Thus, LPPC/TAM, a cati-
onic polymer-liposome composed PEI, helped drug rapidly 
across skin and accumulated in tumor area. In addition, 
drug-loaded LPPC should be able to release the drug in the 
tumor area in a stable (Fig. 1) and controlled manner [17]. 
Therefore, LPPC should give rise to the highly efficient 
penetration of the drug into tumor area.
LPPC provide an advanced encapsulation that was able 
to efficiently deliver TAM into tumor cells. When com-
pared with nonencapsulated TAM, LPPC/TAM not only 
dramatically increased the cytotoxic activity of TAM 
from 6.7- to 7.9-fold in all breast cancer cells in  vitro 
(Fig. 3), but was also able to inhibit 82 % of subcutaneous 
tumor growth in vivo by transdermal treatment (Fig. 5). 
In our previous report found it that LPPC encapsula-
tion could also suppress the cell proliferation of drug-
resistant cells and elevate the anti-proliferative effect of 
drug [22]. The increased antiproliferative effect of LPPC/
TAM may be due to its increased ability to rapid pene-
trate and accumulate in cells. This high level of efficient 
transport into cells is supported by the fact that LPPC is 
a good shuttle carrier for drugs across the cell membrane. 
LPPC has been shown to be an excellent drug trans-
porter, capable of delivering large quantities of encapsu-
lated molecules across the cell membrane quickly, which 
would likely explain the benefits observed by LPPC/TAM 
Fig. 3 Cytotoxicity of LPPC‑TAM in breast cancer cells. a MCF‑7 (ER+), b BT474 (ER+), c MDA‑MB‑231 (ER−) and d human embryonic kidney 
HEK293 cells were treated with different concentrations LPPC, TAM or LPPC/TAM for 72 h. The cell viability was analyzed by MTT cytotoxicity (n = 6)
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treatment in all breast cancer cells containing ER-positive 
and ER-negative cells.
Transdermal drug delivery systems decrease side 
effects and prevent drug from metabolism by systemic 
treatment. Tamoxifen had been approved by FDA for 
breast cancer risk reduction and currently used for 
the treatment of both early and advanced ER positive 
breast cancer. However, the side effects of tamoxifen, 
Fig. 4 In vivo skin permeation of LPPC/DiI or cream/DiI after treatment in BT474 tumor‑bearing mice. a BT474 tumor‑bearing mice were applied 
the cream and LPPC containing DiI fluorescent dye (red fluorescence) to tumor area once. The tumor sample covered with skin were collected and 
fixed at different time periods. All fixed tumor samples were vertically cut and the fluorescent intensity was evaluated for permeation efficiency by 
fluorescent microscope. Hematoxylin & Eosin staining in above panels showed the structure of skin to tumor. Below panel showed the drug accumu‑
lation by skin permeation. b The DiI accumulation in tumor area after treatment with LPPC/DiI or cream/DiI. The fluorescent score were identified as 
0–3 for <5, 5–25, 26–50 and >50 %, respectively
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Fig. 5 Anti‑tumor effects of LPPC/TAM by transdermal treatment. a BT474 tumor‑bearing mice were applied the cream/TAM or LPPC/TAM to tumor 
area every day. Tumor volume was measured with a caliper, and tumor volume was calculated as L × H × W × 0.5236. The animals were sacrificed 
over 60 days after implantation of the 60‑d release 17β‑estradiol pellet (n = 5). b Observations of the skin in the tumor bearing mouse before or 
after treatment with LPPC/TAM. c Histopathological features of the hearts, livers, spleens, lungs, kidneys and intestine in the LPPC/TAM treatment 
group. Portions of the organs were fixed in 10 % formaldehyde overnight, embedded in paraffin and cut into slices. Organ sections were stained 
with H and E
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particularly endometrial cancer and thromboembolic 
complications, have limited the drug’s uptake by high-
risk women who should benefit from its preventive 
effects [12, 23]. In addition, breast cancer patients 
have CYP2D6 polymorphisms associated with loss of 
its enzyme function for tamoxifen metabolism [24]. 
CYP2D6 is a key enzyme for the biotransformation of 
tamoxifen into endoxifen which has more binding activ-
ity of ER than tamoxifen [24]. Breast cancer patients with 
lower CYP2D6 activity caused of their genotype produce 
less endoxifen and lead to inferior therapeutic benefit 
from tamoxifen [25, 26]. Therefore, various tamoxifen 
formulations had been developed for solving side effects 
or metabolism problems of tamoxifen [27–31]. In clini-
cal trials, tamoxifen has already modified the appropriate 
formulations as 4-hydroxytamoxifen gel which success-
fully penetrates the skin to reach breast tissue for a pre-
ventive effect [15, 32]. However, the gel formulation of 
tamoxifen less penetrated at 24 h across skin was similar 
to that in low penetrable liposomal vesicles was limited to 
upper epidermis layer [13, 32]. In our study, LPPC trans-
dermal drug delivery system allowed drug rapidly and 
deeply penetration at 2  h (Fig.  4) and more therapeutic 
effects of tamoxifen (Fig. 5). Thus, transdermal treatment 
of LPPC/TAM might provide the breast cancer patients 
with CYP2D6 polymorphisms another efficient thera-
peutics and avoid the side effects of systemic treatment 
under tamoxifen administration.
Conclusion
We believe that the application of LPPC/TAM as a trans-
dermal treatment have significant potential for prevent-
ing the estrogen-induced proliferative effect on breast 
cancer cells that alleviating future breast cancer develop-
ment and progression.
Methods
Lipo‑PEG‑PEI complex for encapsulating tamoxifen (LPPC/
TAM)
LPPCs were prepared following a previously described 
protocol [33]. For LPPC/TAM preparation, different 
weight ratios of TAM (AstraZeneca, London, UK) and 
1 mg of LPPC were vigorously mixed for 15 s and incu-
bated for 30 min. After incubation, the mixture of tamox-
ifen and LPPC were centrifuged at 5900× g for 5 min to 
remove the free tamoxifen in the supernatant. The pellets 
(LPPC/TAM) were resuspended with 3  ml phosphate-
buffered saline (PBS) buffer for following studies.
Particle size and zeta‑potential of LPPC/TAM
The particle sizes and zeta potentials of the empty LPPC 
and LPPC/TAM were determined using a Zetasizer 
instrument (Zetasizer 3000HS, Malvern Instruments, 
Malvern, UK). To further determine the stability of LPPC/
TAM complexes, the TAM of encapsulated capacity, size 
and zeta potential were also evaluated every week.
TAM encapsulation in LPPC/TAM
To measure the amount of tamoxifen in LPPC, LPPC/
TAMs were destroyed by chloroform and added the dis-
tilled water (DDW) for partition. The concentration of 
TAM remaining in the chloroform layer was then meas-
ured using a UV spectrophotometer (Amersham Bio-
sciences, Uppsala, Sweden) at 300 nm.
In vitro drug release from LPPC/TAM
The in  vitro TAM release from LPPC/TAM complexes 
were evaluated using a dialysis bag diffusion technique. 
LPPC/TAM complexes were suspended in 1  ml of PBS 
and then placed into a dialysis bag (Spectra/Por, Spec-
trum Laboratories Inc., Rancho Dominguez, Califor-
nia) with a 6–8  kDa molecular weight cutoff and was 
immersed into 500  ml of PBS at 4, 25 or 37  °C with 
continuous stirring. LPPC/TAM also incubated in PBS 
with pH 6.0, 7.4 or 8.0 at 37  °C for measuring the drug 
release. Then 1 ml of the sample was collected from the 
incubation medium and measured for TAM concentra-
tion as described above. The release rate was calculated 
as follows:
Cells and culture conditions
Human breast cancer cell lines were such as MDA-
MB-231, MCF-7 and BT474 cells and human embryonic 
kidney 293 cells (HEK293) were purchased from the 
Bioresources Collection and Research Center (Hsinchu, 
Taiwan). All cells were grown in a humidified atmos-
phere with 5 % CO2 at 37 °C and subcultured with a 0.1 % 
trypsin, 2  mM EDTA solution. MDA-MB-231, MCF-7 
and HEK293 cells were maintained in Dulbecco’s Modi-
fied Eagle’s medium (Invitrogen Carlsbad, CA) and BT474 
maintained in HybriCare medium (Invitrogen) supple-
mented with 10  % heat inactivated fetal bovine serum 
(Gibco BRL, Gaithersburg, USA) and 1 % Penicillin/strep-
tomycin (PS, Biological industries, Beithaemek, Israel).
Cytotoxicity of LPPC/TAM
Cells were seeded in 96-well tissue culture plates at a con-
centration of 1 × 104 cells/100 μl/well overnight. Subse-
quently, the cells were treated with serial concentrations 
of the various agents, such as empty LPPC, LPPC/TAM 
and non-encapsulated TAM. After 72  h of incubation, 
the levels of cell viability for each cell line were deter-
mined by MTT colorimetric assay. The cell viability val-
ues were plotted as a percentage of the untreated control. 
Release rate (%) = (Released TAM) amount/
(Total TAM in LPPC) amount × 100%.
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Briefly, 100 µL of 2 mg/mL MTT reagent (Sigma-Aldrich, 
St Louis, MO, USA) was added to each well, and the solu-
tion was allowed to incubate for 5 h at 37  °C. Then, the 
media was aspirated, and 100 µL of dimethyl sulfoxide 
was added to each well. Finally, the OD595 of each well 
was measured by an ELISA reader (Tecan, Mannedorf, 
Switzerland). Cell viability was plotted as a percentage of 
the untreated control.
In vivo skin permeation of LPPC‑DiI and cream‑DiI
Female athymic mice (4–6  weeks of age) were obtained 
from the National Laboratory Animal Center (Taipei, 
Taiwan). All procedures were conducted in compliance 
with the standard operating procedures of the Labora-
tory Animal Center of National Chiao Tung University 
(Hsinchu, Taiwan). Nude mice (n  =  5) were implanted 
s.c. with 2 × 107 BT474 cells suspended in a 50 μL mix-
ture of PBS and Matrigel Matrix High Concentration (BD 
Biosciences, Mountain View, California) at a 1:1 ratio 
after implantation with the 60-d released 17β-estradiol 
pellet (Innovative Research of America, Sarasota, FL). 
BT474 tumor-bearing mice were plastered the cream and 
LPPC containing DiI fluorescent dye (red fluorescence) 
to tumor area until absorption. The tumor sample cov-
ered with skin were collected and fixed at different time 
periods. All fixed tumor samples were vertically cut and 
the fluorescent intensity was evaluated for permeation 
efficiency by the fluorescent microscope.
Anti‑tumor activity of TAM/LPPC
Athymic mice (n = 5) bearing BT474 tumor were treated 
with cream/TAM (containing 25  mg/kg TAM), TAM/
LPPC (containing 25  mg/kg TAM) or vehicle by skin 
applied every day after tumor establishment. Tumor size 
was measured with a caliper, and tumor volume was cal-
culated as L × H × W × 0.5236. The animals were sac-
rificed over 60  days after implantation with the 60-d 
released 17β-estradiol pellet.
Tissue damage in organs
After treatment with TAM/LPPC, the mice were sacri-
ficed. Paraffin-embedded sections were obtained from 
the organs such as heart, liver, spleen, lung, kidney and 
intestine treated with LPPC/TAM by transdermal treat-
ment were processed for H and E staining. Tissue mor-
phology was observed under a microscope (Olympus, 
Center Valley, PA, USA).
Statistical analysis
All analyses were performed using SPSS statistical soft-
ware. Statistical evaluations of data were performed using 
a t test. Datasets with a P value of <0.05 were considered 
significant.
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